EUCTR2011-000535-86-BE
Active, not recruiting
Not Applicable
A PHASE IIb STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ROPIVACAINE COMPARED TO ADRENALINE-LIDOCAINE TO REDUCE PAIN IN PATIENT UNDERGOING SURGERY FOR THIRD MOLAR TEETH EXTRACTION.
CHU AMBROISE PARE0 sites110 target enrollmentFebruary 28, 2011
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- third molar theeth included needing surgical extraction
- Sponsor
- CHU AMBROISE PARE
- Enrollment
- 110
- Status
- Active, not recruiting
- Last Updated
- 11 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Subject undergoing 3rd molar extraction (4 teeth) under generalised anaesthesia
- •Age \= 12 years
- •Subject has given voluntary written informed consent
- •Subject is in the investigator’s opinion, willing and able to comply with the protocol requirements
- •Subject has an ASA scoring of I or II
- •Subject has the following laboratory values at baseline:
- •\-platelet count \= 50x109/L
- •\-PTT \> 40 sec
- •Male or female subject who is post\-menopausal, surgically sterilized or willing to use an acceptable method of birth control for the duration of the study
- •Subject is in the investigator’s opinion able to complete a visual analogue scale
Exclusion Criteria
- •History of parodontal pathology or local inflammation at site of teeth extraction
- •Subject had major surgery within 4 weeks before enrolment
- •Subject with myocardial infarction within 6 months prior enrolment or with NHYA (New York Heart Association) Class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmia or electrocardiographic evidence of acute ischemia or active conduction system abnormalities.
- •Subject has another serious medical condition that could potentially interfere with the completion of treatment according to this protocol or that would impair toleranceto therapy or prolong recovery.
- •Subject has an active systemic infection requiring treatment
- •Female subject is pregnant or breast feeding
- •Subject enrolled in another clinical trial and/or receiving an investigational agent that will contra\-indicate the use of Ropivacaïne® or xylocaïne®. Subjects are allowed to simultaneously participate to non\-investigational trials.
- •Known allergy to Ropivacaïne® or xylocaïne® or other local anesthetics agents of the amide type
- •Patients with ongoing history of epilepsy
- •Chronic treatment with opioïds
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
A PHASE II STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PTK787 IN PATIENTS WITH METASTATIC CUTANEOUS MELANOMAEUCTR2005-004710-33-GBCambridge University Hospitals NHS Foundation Trust34
Active, not recruiting
Phase 1
A PHASE 2/3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF UNESBULIN IN UNRESECTABLE OR METASTATIC, RELAPSED OR REFRACTORY LEIOMYOSARCOMAeiomyosarcomaMedDRA version: 20.0Level: HLTClassification code 10024190Term: LeiomyosarcomasSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2022-000073-12-HUPTC Therapeutics, Inc.345
Active, not recruiting
Phase 1
A PHASE 2/3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF UNESBULIN IN UNRESECTABLE OR METASTATIC, RELAPSED OR REFRACTORY LEIOMYOSARCOMAeiomyosarcomaMedDRA version: 20.0Level: HLTClassification code 10024190Term: LeiomyosarcomasSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2022-000073-12-PLPTC Therapeutics, Inc.345
Active, not recruiting
Phase 1
A PHASE 2/3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF UNESBULIN IN UNRESECTABLE OR METASTATIC, RELAPSED OR REFRACTORY LEIOMYOSARCOMAeiomyosarcomaMedDRA version: 20.0Level: HLTClassification code 10024190Term: LeiomyosarcomasSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2022-000073-12-ESPTC Therapeutics, Inc.345
Active, not recruiting
Phase 1
A PHASE 2/3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF UNESBULIN IN UNRESECTABLE OR METASTATIC, RELAPSED OR REFRACTORY LEIOMYOSARCOMAeiomyosarcomaMedDRA version: 20.0Level: HLTClassification code 10024190Term: LeiomyosarcomasSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2022-000073-12-FRPTC Therapeutics, Inc.345